Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by a variety of cardiac diseases and therapeutic interventions.
This is a prospective study enrolling patients referred for or undergoing cardiovascular procedures or treatment at the University of Kentucky. The study aims to facilitate the discovery of novel diagnostic biomarkers and therapeutic targets and improve the pathophysiological understanding of cardiac conditions.
Study Type
OBSERVATIONAL
Enrollment
400
University of Kentucky
Lexington, Kentucky, United States
RECRUITINGDiscover and quantify the concentration of novel diagnostic and prognostic biomarkers
Use biospecimens procured from patients with cardiac conditions to identify diagnostic surrogate biomarkers using discovery proteomics. In Cardiac Amyloidosis, the serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established. The research aims to advance understanding of cardiac diseases and to support the development of improved therapies.
Time frame: 12/21/2021-12/31/2030
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.